Skip to main content
SpringerLink
Log in

Apolipoproteins in Lipid Disorders

Risk Assessment and Monitoring

  • Book
  • © 1991

Overview

Editors:
  1. Maryvonne Rosseneu

    1. Brugge, Belgium

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Kurt Widhalm

    1. Wien, Austria

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Jochen Jarausch

    1. Mannheim, Federal Republic of Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages I-XII
    Download chapter PDF

  2. Biochemistry and pathophysiology of human plasma apolipoproteins

    • G. M. Kostner
    Pages 1-16

  3. Clinical significance of apolipoprotein measurements

    • M. Rosseneu
    Pages 17-25

  4. Apolipoproteins and coronary heart disease

    • J. P. Deslypere
    Pages 27-40

  5. Apolipoproteins in children with familial history of myocardial infarction

    • K. Widhalm
    Pages 41-48

  6. Apolipoproteins AI and B in health and metabolic disease

    • H. Drexel, Th. Hopferwieser, J. R. Patsch
    Pages 49-61

  7. The clinical relevance of apolipoprotein determination

    • H. Wieland
    Pages 63-68

  8. Development of reagents for apolipoproteins AI and B designed for automated routine determination

    • J. Karl
    Pages 69-77

  9. Results from a European multicentre evaluation of immunoturbidimetric assays for apolipoproteins AI and B

    • J. Jarausch, E. Casals, D. Gnat, H. Drexel, F. X. Huchet, J. Patsch et al.
    Pages 79-94

  10. Standardization of apolipoprotein measurements

    • M. Rosseneu, C. Labeur
    Pages 95-100
Back to top

Keywords

About this book

There is increasing evidence for the clinicial value of the apo­ lipoprotein measurements. Besides cholesterol in plasma and li­ poprotein fractions, which is currently used as an indicator of cardiovascular risk, the measurement of the AI and B apolipopro­ teins can provide additional information about the patients' clinical status. Several studies show that apo B is higher and apo AI is lower in patients with angiographically documented coronary heart dis­ ease than in symptomatic patients without coronary heart disease. Moreover, discriminant analysis indicated that the concentration of Apo AI and B in plasma are better discriminators than lipo­ protein cholesterol for identifying patients with coronary heart disease. In some studies the apo Bjapo AI ratio appears to be a more powerful predictor than individual lipoproteins. In a recent study carried out in men, apolipoproteins AI and B were better correlated with the severity of cardiovascular disease than HDL and LDL cholesterol. The predictive power of apolipoproteins could however not be demonstrated in all studies and the value of apolipoprotein measurements in the field of clinical chemistry is still controversial. This is probably due to discrepancies between the results of various studies, arising from differences in the type of immunoassays, the lack of universal reference materials, differ­ ences between study protocols, variations in the selection of patients and in the grading and interpretation of coronary lesions.

Editors and Affiliations

  • Brugge, Belgium

    Maryvonne Rosseneu

  • Wien, Austria

    Kurt Widhalm

  • Mannheim, Federal Republic of Germany

    Jochen Jarausch

Bibliographic Information

  • Book Title: Apolipoproteins in Lipid Disorders

  • Book Subtitle: Risk Assessment and Monitoring

  • Editors: Maryvonne Rosseneu, Kurt Widhalm, Jochen Jarausch

  • DOI: https://doi.org/10.1007/978-3-7091-9148-4

  • Publisher: Springer Vienna

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag/Wien 1991

  • Softcover ISBN: 978-3-211-82273-9Published: 29 April 1991

  • eBook ISBN: 978-3-7091-9148-4Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XII, 100

  • Number of Illustrations: 28 b/w illustrations

  • Topics: Biochemistry, general, Cardiology, Metabolic Diseases

Publish with us

Policies and ethics

Back to top

Search

Navigation